Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) is now available.
Shanghai HeartCare Medical Technology Corporation Limited has called its first extraordinary general meeting of 2026 for 16 January in Shanghai, where shareholders will vote on a series of governance, capital and structural measures. The agenda includes amendments to the board and shareholders’ meeting rules of procedure, adoption of a management of proceeds policy, approval of a domestic share issuance under a specific mandate and related subscription agreement, as well as granting the board broad authority over the issuance and allowing it to proceed on a non-pre-emptive basis. Shareholders will also consider abolishing the Board of Supervisors and amending the Articles of Association, signalling a potential reshaping of the company’s corporate governance framework and capital structure with implications for shareholder rights and oversight.
The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a PRC-incorporated medical technology company listed in Hong Kong, operating in the healthcare and medical devices sector. The company focuses on developing and commercialising cardiovascular-related medical technologies and products for domestic and international markets.
Average Trading Volume: 56,626
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.09B
See more data about 6609 stock on TipRanks’ Stock Analysis page.